Jump to content

Damoctocog alfa pegol

(Redirected from Jivi)

Damoctocog alfa pegol
Clinical data
Trade namesJivi
Other namesBAY94-9027, antihemophilic factor (recombinant), pegylated-aucl
AHFS/Drugs.comMonograph
License data
Pregnancy
category
Routes of
administration		Intravenous
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
UNII
KEGG
Chemical and physical data
FormulaC7445H11318N1984O2184S69
Molar mass165774.28 g·mol−1

Damoctocog alfa pegol, sold under the brand name Jivi is a recombinant DNA-derived, Factor VIII concentrate used to treat hemophilia A.[5][6]

The most common side effects include headache, cough, nausea, and fever.[5]

Damoctocog alfa pegol was approved for medical use in the United States in August 2018,[7] and in the European Union in November 2018.[6][8]

Medical uses

In the United States damoctocog alfa pegol is indicated for use in previously treated people twelve years of age and older with hemophilia A (congenital Factor VIII deficiency) for on-demand treatment and control of bleeding episodes; perioperative management of bleeding; or routine prophylaxis to reduce the frequency of bleeding episodes.[7]

In the European Union, damoctocog alfa pegol is indicated for the treatment and prophylaxis of bleeding in previously treated people twelve years of age and older with hemophilia A (congenital factor VIII deficiency).[6]

References

  1. ^ a b "Jivi". Therapeutic Goods Administration (TGA). 6 April 2023. Archived from the original on 8 April 2023. Retrieved 7 April 2023.
  2. ^ "Jivi damoctocog alfa pegol 250 IU powder for injection vial with diluent syringe (384590)". Therapeutic Goods Administration (TGA). 28 March 2023. Archived from the original on 8 April 2023. Retrieved 7 April 2023.
  3. ^ https://www.tga.gov.au/resources/auspar/auspar-jivi [bare URL]
  4. ^ "Regulatory Decision Summary for Jivi". 23 October 2014. Archived from the original on 7 June 2022. Retrieved 7 June 2022.
  5. ^ a b c "Jivi (antihemophilic factor- recombinant pegylated-aucl kit". DailyMed. 30 August 2018. Archived from the original on 11 October 2020. Retrieved 1 October 2020.
  6. ^ a b c d "Jivi EPAR". European Medicines Agency (EMA). 24 September 2018. Archived from the original on 2 October 2020. Retrieved 1 October 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  7. ^ a b "Jivi". U.S. Food and Drug Administration (FDA). 29 August 2018. STN: BL 125661. Archived from the original on 30 October 2020. Retrieved 1 October 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  8. ^ Paik J, Deeks ED (July 2019). "Damoctocog Alfa Pegol: A Review in Haemophilia A". Drugs. 79 (10): 1147–1156. doi:10.1007/s40265-019-01152-7. PMC 6711950. PMID 31218660.
  • Clinical trial number NCT01184820 for "Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration" at ClinicalTrials.gov
  • Clinical trial number NCT01580293 for "A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A (PROTECT-VIII)" at ClinicalTrials.gov
  • Clinical trial number NCT01775618 for "Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A" at ClinicalTrials.gov
Retrieved from "https://en.Wik.ipedia.Pro.org/w/index.php?title=Damoctocog_alfa_pegol&oldid=1242361694"

See what we do next...

OR

By submitting your email or phone number, you're giving mschf permission to send you email and/or recurring marketing texts. Data rates may apply. Text stop to cancel, help for help.

Success: You're subscribed now !